论文信息 - A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). - 字舞流文

A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).

J. Sakamoto | Y. Hamamoto | S. Morita | Tatsuro Yamaguchi | T. Nakajima | T. Nishina | K. Yamazaki | T. Ura | N. Nakayama | K. Shimada | A. Goto | Y. Yamada